Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

How to Play Merger Arbitrage Cliff Asness Style

How to play merger arbitrageCliff Asness and AQR Capital’s AQR Delta Master Fund just reported two moves in TMS International Corp. (NYSE:TMS) and Hi-Tech Pharmacal Co. (NASDAQ:HITK).


In a filing with the SEC, AQR reported owning 805,203 shares of TMS International, which have a total value of some $14.07 million, at the current stock price of the company. In a second filing, the fund reported a stake of 5.3% of Hi-Tech Pharmacal, owning 721,655 shares. At the current share price of Hi-Tech Pharmacal, the value of the holding amounts to $31.11 million.

Earlier in August, TMS Internatonal and The Pritzker Organizaton, LLC signed a definitive merger agreement, in terms of which, TMS should be acquired at a price of $17.50 per share with the total value of the deal reaching around $1 billion, TMS said in a statement. The transaction is expected to take place in the last quarter of the year.

Hi-Tech Pharmacal is another pre-merger company. In August the company signed a definitive agreement with Akorn, Inc, which will purchase Hi-Tech Pharmacal offering $43.50 per share for a total value of $640 million, it said in a statement.

Disclosure: none

Recommended Reading:

Fursa Ups Frederick’s Stake Amid Talk That Company May Go Private

Richard Blum Trims His ITT Educational Services Position

Huber Capital Loves Cal Dive, Ups Stake to 17.3%

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!